FierceBiotechOriginal article
{"a":[{"_":"BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data","$":{"href":"/biotech/bristol-myers-dumps-100m-orum-degrader-antibody-conjugate-after-phase-1-look","hreflang":"en"}}]}
Phase 1negativedegrader-antibody conjugateNegative
AI Analysis
Summary
Bristol Myers Squibb has discontinued a degrader-antibody conjugate acquired from Orum Therapeutics for $100 million after unfavorable Phase 1 data. The decision represents a write-off of the acquisition and signals the asset did not meet development criteria.
Clinical Trial Data
Phase
1
Primary Endpoint
Not Met
Outcome Details
BMS discontinued the asset after reviewing Phase 1 data
Importance:6/10
Sentiment:
-0.80
asset_discontinuationPhase_1_failureacquisitiondegraderantibody_conjugate
Related Companies
Read the original article
Published by FierceBiotech on September 18, 2026 3:42 AM